Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 8;39(15):1609–1618. doi: 10.1200/JCO.20.03433

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Response in index lesion size by independent review committee assessment (intent-to-treat population). The best percentage change in the sum of the product of the longest perpendicular dimensions (SPD) during umbralisib treatment, according to assessment by an independent review committee, is shown for patients with MZL, FL, or SLL. Data are shown only for those patients with at least one postbaseline radiographic assessment (N = 198). The majority of patients (86.4%) (with an available scan at data cutoff) showed a decrease in SPD (58 of 64 patients with MZL [90.6%], 96 of 115 patients with FL [83.5%], and 17 of 19 patients with SLL [89.5%]) as assessed by change from baseline. Data cutoff: July 24, 2020. FL, follicular lymphoma; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; SPD, sum of products of perpendicular diameters.